Analyst Price Targets — IRWD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 3:35 pm | Amy Li | Jefferies | $3.70 | $3.60 | StreetInsider | Ironwood Pharmaceuticals (IRWD) PT Raised to $3.70 at Jefferies |
| January 5, 2026 12:27 pm | — | Craig-Hallum | $5.70 | $4.27 | TheFly | Craig-Hallum upgrades Ironwood to Buy following 2026 guidance |
| January 4, 2026 11:22 pm | — | Wells Fargo | $5.00 | $4.27 | TheFly | Ironwood price target raised to $5 from $3 at Wells Fargo |
| November 26, 2025 3:07 pm | — | Craig-Hallum | $3.80 | $3.83 | TheFly | Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum |
| April 14, 2025 3:30 pm | Faisal Khurshid | Leerink Partners | $1.00 | $0.65 | TheFly | Ironwood price target lowered to $1 from $3 at Leerink |
| January 31, 2025 12:05 pm | Mohit Bansal | Wells Fargo | $7.00 | $2.34 | TheFly | Ironwood price target lowered to $7 from $12 at Wells Fargo |
| September 9, 2024 6:26 am | Faisal Khurshid | Leerink Partners | $5.00 | $4.51 | TheFly | Ironwood initiated with a Market Perform at Leerink |
| August 9, 2024 8:24 am | Mohit Bansal | Wells Fargo | $12.00 | $4.05 | TheFly | Ironwood price target lowered to $12 from $14 at Wells Fargo |
| May 22, 2024 7:47 am | David Amsellem | Piper Sandler | $18.00 | $6.82 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD) |
| May 22, 2024 5:13 am | Mohit Bansal | Wells Fargo | $14.00 | $6.78 | StreetInsider | Wells Fargo Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD) |
Latest News for IRWD
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee…
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRWD.
U.S. House Trading
No House trades found for IRWD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.